Belite Bio, Inc (BLTE) Stock Ticker
Market factors today
Unlock the full BLTE picture
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE stock facts
| Ticker symbol | BLTE |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $6.7B |
| CEO | Yu-Hsin Lin |
| Employees | 41 |
| Headquarters | San Diego, CA, US |
| IPO date | 2022-04-29 |
| Website | belitebio.com |
What you can see for BLTE on Tickr
Live BLTE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BLTE report.
Rankings
BLTE peers
FAQ
What is the ticker symbol for Belite Bio, Inc?
The ticker symbol for Belite Bio, Inc is BLTE, listed on the NASDAQ Capital Market.
What is BLTE?
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical…